CD38 and myeloid sarcoma: Similar to the significant difference in DCs detected in patients with early MS in comparison to the healthy controls (cluster 13, Fig. 7a), we also found a decreased frequency of CD141+CD64−CD68−CXCR3+IRF8+ADRP+CD38+ DCs (cluster 3) in patients with CD.